无容量
医学
中止
皮肤病科
转移性黑色素瘤
多形性红斑
红斑
不利影响
黑色素瘤
免疫疗法
易普利姆玛
肿瘤科
重症监护医学
内科学
癌症
癌症研究
作者
Swami Sundaresan,Kathleen T Nguyen,Kelly C. Nelson,Doina Ivan,Anisha B. Patel
摘要
Nivolumab, a relatively novel immune checkpoint inhibitor with FDA approval in 2014, is gaining greater utilization due to its efficacy in treating metastatic melanoma. Many of the cutaneous immune-related adverse events (irAEs) being catalogued do not necessitate discontinuation of immunotherapy and are managed with supportive therapy. We present a case of erythema multiforme major secondary to nivolumab requiring hospitalization and discontinuation of treatment. This is only the second reported case of nivolumab-induced erythema multiforme in the literature we are aware of, and emphasizes the importance of oncologists working in conjunction with dermatologists for prompt diagnosis and management.
科研通智能强力驱动
Strongly Powered by AbleSci AI